Search Within

Matthew J Matasar

  1. "Center for Hematologic Malignancies"
  2. "Colette Owens"
  3. "Ariela Noy"
Formats
  1. Meeting Abstract (21)
  2. Journal Article (14)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (36)
  2. Department of Medicine (36)
  3. Hematologic Malignancies, Division of (36)
  4. Lymphoma (36)
  5. Survivorship Research (36)
  6. Population Sciences Research Program (31)

More Groups

People
  1. Ariela Noy (36)
  2. Colette Owens (36)
  3. Andrew Zelenetz (34)
  4. Maria Palomba (31)
  5. David Straus (30)
  6. Paul Hamlin (30)

More People

Years
  1. 2023 (3)
  2. 2022 (5)
  3. 2021 (12)
  4. 2020 (9)
  5. 2019 (4)
  6. 2017 (1)

More Years

Publications
  1. Blood (19)
  2. Blood Advances (4)
  3. Blood Cancer Journal (3)
  4. Journal of Clinical Oncology (3)
  5. Hematological Oncology (2)
  6. British Journal of Haematology (1)

More Publications

Publishers
  1. American Society of Hematology (23)
  2. American Society of Clinical Oncology (3)
  3. Nature Publishing Group (3)
  4. Wiley Blackwell (2)
  5. Elsevier Inc. (1)
  6. Elsevier Science, Inc. (1)

More Publishers

Results (36)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
    Journal Article

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Moskowitz, A. J.; Stuver, R. N.; Maccaro, C. R.; Galasso, N.; Chang, T.; Khan, N.; Aypar, U.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era
    Research Letter

    Qualls, D.; Imber, B. S.; Okwali, M.; Hamlin, P. A.; Kumar, A.; Lahoud, O. B.; Matasar, M. J.; Noy, A.; Owens, C.; Zelenetz, A. D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma
    Journal Article

    Lin, R. J.; Owens, C. N.; Drill, E.; Iannotta, A.; Oliveros, M.; Schick, D. L.; Noy, A.; Gerecitano, J. F.; Drullinsky, P. R.; Caron, P. C.; more...
    Haematologica (2022)

    Fulltext@MSK | Save
  • Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: A single-center experience
    Journal Article

    Pak, T. K.; Dixon, B. N.; Buege, M. J.; Dao, P. H.; Leary, M. H.; Jarrett, J. C.; Duggan, T. A.; Caron, P.; Falchi, L.; Hamlin, P.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save